End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
42.15 CNY | -0.94% | -8.07% | -32.64% |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- With a 2023 P/E ratio at 27.33 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-32.64% | 2.75B | B- | ||
-16.65% | 8.34B | B+ | ||
+40.49% | 3.59B | C+ | ||
-8.06% | 2.48B | - | ||
-9.58% | 2.32B | B- | ||
-14.40% | 1.79B | C- | ||
-18.74% | 1.54B | A- | ||
-40.19% | 1.21B | C+ | ||
+5.57% | 1.13B | B+ | ||
-14.72% | 992M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 603882 Stock
- Ratings Guangzhou Kingmed Diagnostics Group Co., Ltd.